Rhode Island Hospital

Roger Williams General Hospital

Other

Rhode Island Hospital, a Lifespan-partner

The Salk Institute for Biological Studies

Brown University

Carter Wallace, Inc.

Geistlich Phama Ag

Geistlich Pharma Ag

Paul Calabresi

James W Darnowski

Michael C Wiemann

Ming Y Chu

Andrew J Baird

Douglas A Lappi

James C Costin

Mahmoud H El Kouni

A Raymond Frackelton, Jr

Fardos N Naguib

Sungman Cha

Shih H Chu

Bai-Chuan Pan

Jeffrey W Clark

Julie G Beitz

James Darnowski

The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing taurolidine, taurultam, or a biologically active derivative thereof. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.

Use of taurolidine to treat tumors

Methods of treating tumors

The invention provides a method of inhibiting tumor growth in a mammal, by administering to the mammal composition containing methylol-containing compound. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death by apoptosis.

Use of a methylol-containing compound to treat tumors

The invention provides antineoplastic composition containing an inhibitor of angiogenesis and an inhibitor of DNA topoisomerase type I enzyme activity.

Combination drug therapy

The invention provides a method of inhibiting tumor growth by contacting the tumor with a composition containing a taurine compound. The composition is administered to directly contact a tumor cell at a dose sufficient to induce cell death.

Taurine compounds

Methods of treating tumors with taurolidine

Combinations of 3&prime;-azido-3&prime;-deoxythymidine (AZT) with 5-fluorouracil (FUra) or its precursor 5-fluoro-2&prime;-deoxyuridine (FUDR) or methoxtrexate (MTX) exhibit increased cytotoxicity and increased therapeutic index in treatment of carcinomas.

Drug cominbations containing AZT

Conjugates comprising bFGF or other FGF polypeptides and a cytotoxic agent are prepared. The cytotoxic agent can be a ribosome-inactivating protein (RIP), such as saporin, which is attached to bFGF through a chemical bond, or the composition can be prepared as a recombinant DNA chimera. The conjugates are used to specifically target cells, in vivo and in vitro, which express FGF receptors. The cytotoxicity of the conjugates is proportional to the number of receptors expressed by a cell type. The conjugate is useful to effectively treat mammals, and in particular human patients, afflicted with tumorigenic conditions, such as human melanomas, human ovarian carcinomas, teratocarcinomas and neuroblastomas, and other FGF-mediated tumors caused by a proliferation of cells which express FGF receptors.

Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic

Combinations of 3'-azido-3'-deoxythymidine (AZT) with 5-fluorouracil (FUra) or its precursor 5-fluoro-2'-deoxyuridine (FUDR) or methoxtrexate (MTX) exhibit increased cytotoxicity and increased therapeutic index in treatment of carcinomas.

Drug combinations containing AZT

The invention is directed to a method of inhibiting anemia caused by the administration of AZT to a patient which comprises administering to said patient an effective anemia-inhibiting amount of a combination of dipyridamole and 5-benzylacyclouridine. The invention is further directed to a pharmaceutical composition comprising as the active pharmaceutical agent a combination of dipyridamole and 5-benzylacyclouridine in association with a pharmaceutically acceptable carrier or diluent.

Reduction of the severity of 3'-azido-3'-deoxythymidine-induced anemia

A method of reducing anemia caused by the administration of 3'-azido-3'-deoxythymidine to an animal which comprises treating said animal with a compound which inhibits the enzyme uridine phosphorylase in order to increase cellular uridine levels is disclosed. A particularly-effective compound is 5-benzylacyclouridine.

Reduction of the severity 3'-azido-3'-deoxythymidine-induced anemia

A compound of the Formula (I): ##STR1## where X is a benzyl group or a benzyloxybenzyl group and pharmaceutical preparations containing the same.

Growing community of inventors

Barrington, RI, United States of America

Paul Calabresi